Weight management
Reduction or stabilisation of body weight in overweight or obesity. Clinical endpoints: percentage weight loss, waist circumference, comorbidities. Weight regain after discontinuation is a central topic of discussion.
Peptides on this topic
6 peptides researched for this topicSynthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet.
- Human RCTAdditional weight reduction in combination with semaglutide 2.4 mg versus semaglutide monotherapy observed in the phase-2 CagriSema trial
- Human RCTMonotherapy showed weight reduction of similar magnitude to GLP-1 RA comparator arms in a phase-2 study
GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014).
- Human RCTReduction in cardiovascular events (MACE) in type-2-diabetes patients at high CV risk over 3.8 years
- Human RCTMean weight loss in adults with obesity over 56 weeks in the SCALE trial
Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet.
- Human RCTWeight reduction over 48 weeks observed in the phase-2 obesity trial — at the highest dose greater than documented for other incretin-based therapies
- Human RCTHbA1c reduction in type 2 diabetes over 36 weeks documented in a phase-2 trial
Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs.
- Human RCTReduction of HbA1c in type-2 diabetes
- Human RCTWeight reduction in overweight and obesity
Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet.
- Human RCTWeight reduction over 46 weeks documented in a phase-2 obesity trial
- Human RCTHistological MASH improvement reported in a phase-2 trial over 48 weeks
Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound).
- Human RCTReduction in HbA1c versus placebo and versus semaglutide observed in randomised trials
- Human RCTWeight loss over 72 weeks in the obesity-without-diabetes study population